Evaluating Tumor Heterogeneity with a High Throughput Pipeline

An automated bioprinting and imaging platform allows researchers to examine heterogeneous responses to anticancer drugs within a tumor organoid population.

Charlene Lancaster, PhD
| 3 min read
Images of tumor organoids acquired using high-speed live cell interferometry.

Alice Soragni and her team used their high-speed live cell interferometry-based platform to acquire images like this one, which displays bioprinted cancer cell line clusters over the course of 72 hours.

Peyton Tebon and Bowen Wang

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The success of nonclinical drug testing relies heavily on using models that accurately recapitulate complex biological processes. With the passing of the Food and Drug Administration (FDA) Modernization Act 2.0 in 2022, researchers are no longer required to employ animal models to screen drug candidates.1 Instead, the FDA is encouraging scientists to use other models, such as three-dimensional organoids and artificial intelligence-based methods, which are more predictive of the human response.2 As a result, researchers will need to improve existing methods and develop new protocols to optimize the efficiency of nonclinical testing. In a proof-of-concept Nature Communications paper, scientists developed an automated high throughput assay to monitor tumor organoid growth label-free.3

“3D screening in a high throughput manner is still very challenging,” said Alice Soragni, a cancer biologist at the University of California, Los Angeles (UCLA) and co-corresponding author of this study along with Michael Teitell at UCLA. Normally, researchers manually seed organoids within a 3D extracellular matrix, such as Matrigel, which is either spread across the surface of a microplate’s well or placed as a drop in the center of the well. However, this methodology prevents scientists from implementing automated liquid handlers, which would disturb the organoids grown in the center of each well. To overcome this hurdle, Soragni, Teitell, and their interdisciplinary team developed a strategy to bioprint cancer cell line clusters suspended in culture medium and Matrigel into a microplate’s wells. The bioprinter extruded the mixture in the shape of a hollow square, leaving a clearing in the center of each well. Because they could now employ automated liquid handlers, the researchers could increase the pipeline’s throughput.

The researchers also wanted to develop a method for observing how individual tumor organoids respond to therapy in real time. Scientists commonly use endpoint assays to assess a drug’s effect on an organoid population, but these tests fail to evaluate intra-sample heterogeneity. Soragni and her colleagues instead employed high-speed live cell interferometry, which is a label-free optical technique that uses phase shifts generated when light passes through an object to calculate its mass. Using this imaging method and machine learning-based quantitation, the researchers evaluated how individual tumor organoids responded to treatment with anticancer drugs by monitoring their biomass. Cell populations arising from the same line are often assumed to be homogenous, but after treatment the researchers observed organoids increasing, decreasing, or maintaining their size. These findings highlighted the pipeline’s potential for detecting heterogeneous drug responses.

“It is very nice to have an interdisciplinary group working together to figure out what we can do better,” said Lanlan Zhou, a cancer biologist and the director of the Organoid Core Facility located within the Legorreta Cancer Center at Brown University, who was not involved in the study. Zhou was excited to see what the group would do next and hoped they would test their platform’s ability to assess more complex organoid models that better represent the tumor microenvironment in vivo. “You do have to think about the tumor microenvironment because the tumor is not only made of tumor cells. It is made of many cells including some normal cells. For example, they have immune cells, they have fibroblasts, they have blood vessels.”

Soragni, Teitell, and their team are currently investigating how patient-derived organoids will react to bioprinting in hopes that they can use this platform to predict patient drug responses. This will be of particular importance for rare cancers, such as sarcomas. “For the majority of rare cancers, we have very little knowledge. We do not know what are the drivers of disease, we do not know how heterogeneous they are, we do not know how they respond to therapy,” Soragni said. “Looking with this type of platform at rare cancer is going to give us a lot of information. It is going to teach us a lot of biology and it is going to also help us potentially come up with therapies we could be looking at clinically.”

Keywords

Meet the Author

  • Charlene Lancaster, PhD

    Charlene Lancaster, PhD

    Charlene earned her MSc and PhD in cell biology from the University of Toronto and currently serves as an assistant science editor for The Scientist's Creative Services team.
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio